ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases)

ERN-EuroBloodNet, the ERN in Rare Hematological Diseases (RHD) was officially approved by the European Commission (EC) on December 2016 and started its activity 1st March 2017. ERN-EuroBloodNet results from a joint effort of the European Hematology Association (EHA), the European Network on Rare and Congenital Anaemias (ENERCA), the European hematology patient organisations represented in both the EURORDIS European Patient Advocacy Groups (ePAGS) and the EHA Patient Organisations Workgroup. ERN-EuroBloodNet encompasses oncological and non-oncological rare hematological diseases including rare anemias, rare coagulation disorders, polycythemia, and myeloid and lymphoid tumors. Rare hereditary hemochromatosis was also included in our network following a request...

Ern-eurobloodnet (european reference network on rare hematological diseases) operates in the Hospitals and health care industry.

Ern-eurobloodnet (european reference network on rare hematological diseases)'s revenue is 11m - 100m

Ern-eurobloodnet (european reference network on rare hematological diseases) has 11 - 50 employees.